David FitzPatrick MD Inc — research payments reported

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$620,532	33
2024	Research	$788,468	38
2023	Research	$3,130,527	86
2022	Research	$4,195,491	77
2021	Research	$4,129,873	106
2020	Research	$27,125	2
2019	Research	$36,935	13

Breakdown

Who paid Research payments · program years 2019–2025

Pfizer Inc. $12,888,064 345 payments
Sanofi US Services Inc. $40,887 10 payments

Studies the money was for Research payments · program years 2019–2025

A Phase 3 Randomized Observerblinded Study to Evaluate the Efficacy Safety Tolerability and Immunogenicity of A Modified Rna Vaccine Against Influenza Compared to Licensed Inactivated Influenza Vaccine in Healthy Adults 18 Years of Age Or Older $3,052,222 43 payments
A Phase 3 Master Protocol to Evaluate Additional Doses of Bnt162b2 in Healthy Individuals Previously Vaccinated With Bnt162b2 $2,987,187 39 payments
A Phase 123 Placebocontrolled Randomized Observerblind Dosefinding Study to Evaluate the Safety Tolerability Immunogenicity and Efficacy of Sarscov2 Rna Vaccine Candidates Against Covid19 in Healthy Adults $2,942,897 75 payments
A Phase 3 Randomized Observerblind Study to Evaluate the Safety Tolerability and Immunogenicity of Multiple Production Lots and Dose Levels of the Vaccine Candidate Bnt162b2 Against Covid19 in Healthy Participants 12 Through 50Years of Age and the Safety Tolerability and Immunogenicity of Bnt162b2 Rnabased Covid19 Vaccine Candidates As A Booster Dose in Healthy Participants 18 Through 50Years of Age $596,982 14 payments
An Interventional Randomized Activecontrolled Phase 23 Study to Investigate the Safety Tolerability and Immunogenicity of Bivalent Bnt162b Rnabased Vaccine Candidates As A Booster Dose in Covid19 Vaccineexperienced Healthy Individuals $523,850 30 payments
A Phase 23 Protocol to Investigate the Safety Tolerability and Immunogenicity of Bnt162b2 Rnabased Vaccine Candidates for Sarscov2 New Variants in Healthy Individuals $521,209 24 payments
A Phase 1 Randomized Study to Evaluate the Safety Tolerability and Immunogenicity of Combined Modified Rna Vaccine Candidates Against Covid19 and Influenza in Healthy Individuals $292,722 6 payments
A Phase 12 Randomized Observerblind Study to Evaluate the Safety Tolerability and Immunogenicity of A Modified Rna Vaccine Against Varicella Zoster Virus in Healthy Individuals $273,902 13 payments
A Phase 12 Randomized Observerblinded Study to Evaluate the Safety Tolerability and Immunogenicity of Combined Vaccine Candidates Against Influenza and Covid19 in Healthy Individuals $224,566 5 payments
A Phase 12 Randomized Study to Evaluate the Safety Tolerability and Immunogenicity of A Modified Rna Vaccine Against Influenza in Healthy Individuals $217,916 14 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.